Related Experiment Video
Updated: Jan 27, 2026

Culture of Bladder Cancer Organoids as Precision Medicine Tools
Published on: December 28, 2021
Ushering in the next generation of precision trials for pediatric cancer
Steven G DuBois1,2,3, Laura B Corson1,2, Kimberly Stegmaier1,2,3
1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Abstract:
Cancer treatment decisions are increasingly based on the genomic profile of the patient's tumor, a strategy called "precision oncology." Over the past few years, a growing number of clinical trials and case reports have provided evidence that precision oncology is an effective approach for at least some children with cancer. Here, we review key factors influencing pediatric drug development in the era of precision oncology. We describe an emerging regulatory framework that is accelerating the pace of clinical trials in children as well as design challenges that are specific to trials that involve young cancer patients. Last, we discuss new drug development approaches for pediatric cancers whose growth relies on proteins that are difficult to target therapeutically, such as transcription factors.
Insights
Precision oncology is improving outcomes for children with cancer. This review covers factors, regulations, and challenges in developing targeted pediatric cancer drugs, including those targeting difficult proteins.
Area of Science:
- Oncology
- Genomics
- Pediatric Medicine
Background:
- Precision oncology, guided by tumor genomic profiles, is transforming cancer treatment.
- Evidence supports precision oncology's effectiveness in pediatric cancer patients.
- Pediatric drug development faces unique challenges in the era of targeted therapies.
Purpose of the Study:
- To review key factors influencing pediatric drug development for precision oncology.
- To discuss the evolving regulatory landscape for pediatric cancer clinical trials.
- To explore novel approaches for targeting difficult-to-treat pediatric cancers.
Main Methods:
- Review of current literature on precision oncology in pediatric cancer.
- Analysis of regulatory frameworks impacting pediatric drug trials.
- Discussion of challenges and innovations in pediatric cancer drug development.
Main Results:
- Precision oncology demonstrates efficacy in specific pediatric cancer cases.
- An emerging regulatory framework is expediting pediatric clinical trials.
- Specific design challenges exist for pediatric cancer clinical trials.
- New strategies are needed for targeting challenging proteins like transcription factors.
Conclusions:
- Precision oncology offers significant promise for treating childhood cancers.
- Regulatory adaptations are crucial for advancing pediatric targeted therapies.
- Addressing unique pediatric trial designs and therapeutic targets is essential for future progress.
Related Concept Videos
Uncertainty in Measurement: Accuracy and Precision
Clinical Trials: Overview
Trial and Error and Algorithm
Clinical Trials
There are four phases in a clinical trial. A phase one...
Accuracy and Precision
Pharmacokinetics in Pediatric Patients: Drug Excretion

